Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial
Authors:
Open Access
- 22 February 2022
- journal article
- research article
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (7) , 628-637
Abstract
No abstract availableKeywords
Funding Information
- Allergan
- GlaxoSmithKline
- Novartis Pharma AG
- Novartis
- Shire
- NIHR Great Ormond Street Hospital Biomedical Research Centre
- Bayer
- Roche
This publication has 19 references indexed in Scilit:
- Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of PrematurityJAMA Pediatrics, 2018
- Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of PrematurityOphthalmology, 2017
- COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITYRetina, 2017
- Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk FactorsInvestigative Ophthalmology & Visual Science, 2017
- Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab MonotherapyOphthalmology, 2016
- Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal BevacizumabOphthalmic Surgery, Lasers and Imaging Retina, 2016
- Comparison of Binding Characteristics and In Vitro Activities of Three Inhibitors of Vascular Endothelial Growth Factor AMolecular Pharmaceutics, 2014
- Vitreous Levels of Stromal Cell–Derived Factor 1 and Vascular Endothelial Growth Factor in Patients with Retinopathy of PrematurityOphthalmology, 2008
- The International Classification of Retinopathy of Prematurity RevisitedArchives of Ophthalmology (1950), 2005
- Quantile Regression Models with Multivariate Failure Time DataBiometrics, 2005